Judith‐Anne W. Chapman

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31

Karen A. Gelmon, Frances Boyle, Bella Kaufman et al. · Journal of Clinical Oncology · 2015 · 183 citations · Full text

Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer

Margot J. Burnell, Mark N. Levine, Judith‐Anne W. Chapman et al. · Journal of Clinical Oncology · 2009 · 152 citations · Full text

Surgical Oncology, Breast Oncology, Cancer Management +18

Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14

Kathleen I. Pritchard, Lois E. Shepherd, Judith‐Anne W. Chapman et al. · Journal of Clinical Oncology · 2011 · 85 citations · Full text

Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial

Vered Stearns, Judith‐Anne W. Chapman, X. Cynthia et al. · Journal of Clinical Oncology · 2014 · 42 citations · Full text

Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial

Vivien Bramwell, Alan B. Tuck, Judith‐Anne W. Chapman et al. · Breast Cancer Research · 2014 · 42 citations · Full text